Evidence map›Paper›PMID 39310428›Full record

ArticleCureus2024

Increasing Importance and Costs Associated With Publishing for Dermatology Residency Applicants.

Hafsa Z Zuberi, Nathan Steele, Jonathan Aldrete, Cloyce Stetson

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hafsa Z ZuberiSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Nathan SteeleSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Jonathan AldreteDepartment of Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.
Cloyce StetsonDepartment of Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The financial costs associated with publishing in academic journals have steadily risen in recent years, reflected by higher publishing fees and the emergence of open access (OA) publishing models. Research remains an essential part of academia and has special significance for residency applicants. Due to recent changes in some objective measures used to rank residency applicants, such as abandoning numerical United States Medical Licensing Examination (USMLE) Step 1 scores and transitioning pre-clinical grades to Pass/Fail, other objective measures have gained significance: in particular, the quality and quantity of research activities including manuscripts, abstracts, and presentations have become more important in residency applications. This has led to a significant increase in the reported number of research experiences and publications to more competitive specialties, including dermatology. Our study analyzes the current financial landscape of publishing in the field of dermatology and the financial burden placed on applicants as well as programs to meet the expected number of research experiences in order to successfully match into a dermatology residency. Through a comprehensive examination of 85 dermatology-based academic journals, we assess the costs and differences of publishing in OA and hybrid OA journals while also exploring potential avenues for mitigating the financial burden of publishing. Our findings indicate that while cost-effective options exist, the financial burden of article processing charges remains substantial.

Indexed as

dermatologymedical educationresearchresidency applicationsscholarly activity

Identifiers

PMID39310428
PMCPMC11416181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.